Neuromeka Amends Supply Contract with POSCO Extending End Date, No New Financing

Neuromeka amended its single sales and supply contract disclosure on June 30, 2026, extending the contract end date with POSCO to March 31, 2027.
The contract amount remains unchanged at KRW 2.935 billion, representing 11.61% of its 2024 consolidated revenue.
This revision is an administrative step due to a change in the contract period, involving no additional fundraising or financial alteration.
Payment terms including down payment, interim payment, and final payment schedules remain unchanged.
[AI Summary]Neuromeka's amendment to extend the supply contract with POSCO is a schedule adjustment without altering core terms, thus limited impact on shareholder value. No dilution risk as no new capital is raised, supporting stable revenue generation.